Актуальна ли терапия инфликсимабом в настоящее время у пациентов с воспалительными заболеваниями кишечника? (обзор литературы)

ВВЕДЕНИЕ: в настоящее время в лечении среднетяжёлых форм воспалительных заболеваний кишечника (ВЗК) активно используются генно-инженерные препараты (ГИБП) и таргетные иммуносупрессоры (ТИС). Несмотря на значительное улучшение исходов заболеваний, улучшения качества жизни пациентов и снижение хирургической активности, в долгосрочной перспективе полноценной клинико-инструментальной ремиссии нередко достигнуть не удается, или с течением времени ответ теряется.
ЦЕЛЬ: систематизация данных об эффективности и безопасности терапии ВЗК инфликсимабом, а также методам ранней и поздней оценки эффективности; показаниям, видам и особенностям оптимизации терапии.
ВЫВОДЫ: несмотря на появление сравнительно большого количества новых ГИБП и ТИС, остается проблема неэффективности или потери ответа. На наш взгляд, решением этой проблемы может быть персонификация назначения и режимов терапии ГИБП. В настоящее время есть немало исследований, посвященных как клиническим, так и лабораторным маркерам, имеющим прогностическое значение в ведении пациентов с ВЗК при терапии инфликсимабом. Однако эти исследования не валидированы для российской популяции пациентов. Требуется проведение многоцентровых исследований на российской популяции пациентов.

1. Будзинская А.А., Белоусова Е.А., Вакурова Е.С., и соавт. Эндосонографические изменения поджелудочной железы у больных с воспалительными заболеваниями кишечника и хроническим панкреатитом. Экспериментальная и клиническая гастроэнтерология. 2023;(3):53–60. doi: 10.31146/1682-8658-ecg-211-3-53-60

2. Darie AM, Sinopoulou V, Ajay V, et al. BSG 2024 IBD guidelines protocol (standard operating procedures). BMJ Open Gastroenterol. 2023 Feb;10(1):e001067. doi: 10.1136/bmjgast-2022-001067

3. Elliott MJ, Maini RN, Feldmann M, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet. 1994;344(8930):1105–10. doi: 10.1016/s0140-6736(94)90628-9

4. Targan SR, Hanauer SB, van Deventer SJH, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. N Engl J Med. 1997;337(15):1029–35

5. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359(9317):1541–9. doi: 10.1016/S0140-6736(02)08512-4

6. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353(23):2462–76. doi: 10.1056/NEJMoa050516

7. Kim NH, Lee JH, Hong SN, et al. Long-term efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: A retrospective multicenter study. J Gastroenterol Hepatol. 2019;34(9):1523–1532. doi: 10.1111/jgh.14645

8. Nencini F, Vultaggio A, Pratesi S, et al. The Kinetics of Antidrug Antibodies, Drug Levels, and Clinical Outcomes in Infliximab-Exposed Patients with Immune-Mediated Disorders. J Allergy ClinImmunol Pract. 2018;6(6):2065–2072.e2. doi: 10.1016/j.jaip.2018.04.007

9. Нуриахметова Т.Ю., Валеева И.Х., Шевнина Я.О., и соавт. Эффективность ингибиторов фактора некроза опухоли α в лечении различных иммуновоспалительных заболеваний: фокус на иммуногенность. Современная ревматология. 2023;17(4):35–41. doi: 10.14412/1996-7012-2023-4-35-41

10. Reinisch W, Gecse K, Halfvarson J, et al. Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn’s Disease. Inflamm Bowel Dis. 2021;27(1):106–122. doi: 10.1093/ibd/izaa078

11. Tsui JJ, Huynh HQ. Is top-down therapy a more effective alternative to conventional step-up therapy for Crohn’s disease? Ann Gastroenterol. 2018;31(4):413–424. doi: 10.20524/aog.2018.0253

12. Papamichael K, Vajravelu RK, Osterman MT, et al. Long-Term Outcome of Infliximab Optimization for Overcoming Immunogenicity in Patients with Inflammatory Bowel Disease. Dig Dis Sci. 2018;63(3):761–767. doi: 10.1007/s10620-018-4917-7

13. Feng T, Chen B, Ungar B, et al. Association of Infliximab Levels With Mucosal Healing Is Time-Dependent in Crohn’s Disease: Higher Drug Exposure Is Required Postinduction Than During Maintenance Treatment. Inflamm Bowel Dis. 2019;25(11):1813–1821. doi: 10.1093/ibd/izz061

14. Papamichael K, Vande Casteele N, Jeyarajah J, et al. Higher Postinduction Infliximab Concentrations Are Associated With Improved Clinical Outcomes in Fistulizing Crohn’s Disease: An ACCENT-II Post Hoc Analysis. Am J Gastroenterol. 2021;116(5):1007–1014. doi: 10.14309/ajg.0000000000001111

15. Koga A, Matsui T, Takatsu N, et al. Trough level of infliximab is useful for assessing mucosal healing in Crohn’s disease: a prospective cohort study. Intest Res. 2018;16(2):223–232. doi: 10.5217/ir.2018.16.2.223

16. Blanchard F, Wang Y, Kinzie E, et al. Oncostatin M regulates the synthesis and turnover of gp130, leukemia inhibitory factor receptor alpha, and oncostatin M receptor beta by distinct mechanisms. J Biol Chem. 2001;276(50):47038–45. doi: 10.1074/jbc.M107971200

17. Кручинина М.В., Светлова И.О., Осипенко М.Ф., и соавт. Значимость уровней сывороточных маркеров для оценки статуса и прогноза больных с воспалительными заболеваниями кишечника. Экспериментальная и клиническая гастроэнтерология. 2023;212(4):121–132. doi: 10.31146/1682-8658-ecg-212-4-121-132

18. Bertani L, Fornai M, Fornili M, et al. Serum oncostatin M at baseline predicts mucosal healing in Crohn’s disease patients treated with infliximab. Aliment Pharmacol Ther. 2020;52(2):284–291. doi: 10.1111/apt.15870

19. Verstockt B, Verstockt S, Dehairs J, et al. Low TREM1 expression in whole blood predicts anti-TNF response in inflammatory bowel disease. E Bio Medicine. 2019;40:733–742. doi: 10.1016/j.ebiom.2019.01.027

20. Andreou NP, Legaki E, Dovrolis N, et al. B-cell activating factor (BAFF) expression is associated with Crohn’s disease and can serve as a potential prognostic indicator of disease response to Infliximab treatment. Dig Liver Dis. 2021 May;53(5):574–580. doi: 10.1016/j.dld.2020.11.030

21. Jahnsen J, Kaasen Jørgensen K. Experience with Biosimilar Infliximab (Remsima®) in Norway. Dig Dis. 2017;35(1-2):83–90. doi: 10.1159/000449088.21

22. Lega S, Phan BL, Rosenthal CJ, et al. Proactively Optimized Infliximab Monotherapy Is as Effective as Combination Therapy in IBD. Inflamm Bowel Dis. 2019;25(1):134–141. doi: 10.1093/ibd/izy203

23. D’Haens G, Vermeire S, Lambrecht G, et al. Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn’s Disease. Gastroenterology. 2018;154(5):1343–1351.e1. doi: 10.1053/j.gastro.2018.01.004

24. Papamichael K, Rakowsky S, Rivera C, et al. Association Between Serum Infliximab Trough Concentrations During Maintenance Therapy and Biochemical, Endoscopic, and Histologic Remission in Crohn’s Disease. Inflamm Bowel Dis. 2018;24(10):2266–2271. doi: 10.1093/ibd/izy132

25. Fernandes SR, Bernardo S, Simões C, et al. Proactive Infliximab Drug Monitoring Is Superior to Conventional Management in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2020;26(2):263–270. doi: 10.1093/ibd/izz131

26. Fernandes SR, Serrazina J, Rodrigues IC, et al. Proactive therapeutic drug monitoring is more effective than conventional management in inducing fecal calprotectin remission in inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2021;33(12):1539–1546. doi: 10.1097/MEG.0000000000002111

27. Ricciuto A, Dhaliwal J, Walters TD, et al. Clinical Outcomes With Therapeutic Drug Monitoring in Inflammatory Bowel Disease: A Systematic Review With Meta-Analysis. J Crohns Colitis. 2018;12(11):1302–1315. doi: 10.1093/ecco-jcc/jjy109

28. Papamichael K, Vajravelu RK, Vaughn BP, et al. Proactive Infliximab Monitoring Following Reactive Testing is Associated With Better Clinical Outcomes Than Reactive Testing Alone in Patients With Inflammatory Bowel Disease. J Crohns Colitis. 2018;12(7):804–810. doi: 10.1093/ecco-jcc/jjy039

29. Hoseyni H, Xu Y, Zhou H. Therapeutic Drug Monitoring of Biologics for Inflammatory Bowel Disease: An Answer to Optimized Treatment? J Clin Pharmacol. 2018;58(7):864–876. doi: 10.1002/jcph.1084

30. Laterza L, Ainora ME, Garcovich M, et al. Bowel contrastenhanced ultrasound perfusion imaging in the evaluation of Crohn’s disease patients undergoing anti-TNFα therapy. Dig Liver Dis. 2021;53(6):729–737. doi: 10.1016/j.dld.2020.08.005

31. Targownik LE, Benchimol EI, Bernstein CN, et al. Combined Biologic and Immunomodulatory Therapy is Superior to Monotherapy for Decreasing the Risk of Inflammatory Bowel Disease-Related Complications. J Crohns Colitis. 2020;14(10):1354–1363. doi: 10.1093/ecco-jcc/jjaa050

32. Targownik LE, Benchimol EI, Bernstein CN, et al. Upfront Combination Therapy, Compared With Monotherapy, for Patients Not Previously Treated With a Biologic Agent Associates With Reduced Risk of Inflammatory Bowel Disease-related Complications in a Population-based Cohort Study. Clin Gastroenterol Hepatol. 2019;17(9):1788–1798.e2. doi: 10.1016/j.cgh.2018.11.003

33. Mogensen DV, Brynskov J, Ainsworth MA, et al. A Role for Thiopurine Metabolites in the Synergism BetweenThiopurines and Infliximab in Inflammatory Bowel Disease. J Crohns Colitis. 2018;12(3):298–305. doi: 10.1093/ecco-jcc/jjx149

34. Colombel JF, Adedokun OJ, Gasink C, et al. Combination Therapy With Infliximab and Azathioprine Improves Infliximab Pharmacokinetic Features and Efficacy: A Post Hoc Analysis. Clin Gastroenterol Hepatol. 2019;17(8):1525–1532.e1. doi: 10.1016/j.cgh.2018.09.033

35. Mattoo VY, Basnayake C, Connell WR, et al. Systematic review: efficacy of escalated maintenance anti-tumour necrosis factor therapy in Crohn’s disease. Aliment Pharmacol Ther. 2021;54(3):249–266. doi: 10.1111/apt.16479

36. Drobne D, Kurent T, Golob S, et al. Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel disease. Aliment Pharmacol Ther. 2019;49(7):880–889. doi: 10.1111/apt.15179

37. Srinivasan A, Vasudevan A, McFarlane A, et al. Anti-TNF Re-induction Is as Effective, Simpler, and Cheaper Compared With Dose Interval Shortening for Secondary Loss of Response in Crohn’s Disease. J Crohns Colitis. 2018;12(3):280–288. doi: 10.1093/eccojcc/jjx144

38. Drobne D, Kurent T, Golob S, et al. Success and safety of high infliximab trough levels in inflammatory bowel disease. Scand J Gastroenterol. 2018;53(8):940–946. doi: 10.1080/00365521.2018.1486882

39. Syversen SW, Jørgensen KK, Goll GL, et al. Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial. JAMA. 2021;326(23):2375–2384. doi: 10.1001/jama.2021.21316

40. Barclay ML, Karim S, Helms ETJ, et al. Infliximab and adalimumab concentrations and anti-drug antibodies in inflammatory bowel disease control using New Zealand assays. Intern Med J. 2019;49(4):513–518. doi: 10.1111/imj.14064

41. Pouillon L, Ferrante M, Van Assche G, et al. Mucosal Healing and Long-term Outcomes of Patients With Inflammatory Bowel Diseases Receiving Clinic-Based vs Trough Concentration-Based Dosing of Infliximab. Clin Gastroenterol Hepatol. 2018;16(8):1276–1283.e1. doi: 10.1016/j.cgh.2017.11.046

42. Strik AS, Löwenberg M, Mould DR, et al. Efficacy of dashboard driven dosing of infliximab in inflammatory bowel disease patients; a randomized controlled trial. Scand J Gastroenterol. 2021;56(2):145–154. doi: 10.1080/00365521.2020.1856405

43. Kamperidis N, Middleton P, et al. Impact of therapeutic drug level monitoring on outcomes of patients with Crohn’s disease treated with Infliximab: real world data from a retrospective single centre cohort study. Frontline Gastroenterol. 2019 Oct;10(4):330–336. doi: 10.1136/flgastro-2018-101024

44. Sánchez-Hernández JG, Rebollo N, Martin-Suarez A, et al. A 3-year prospective study of a multidisciplinary early proactive therapeutic drug monitoringprogramme of infliximab treatments in inflammatory bowel disease. Br J Clin Pharmacol. 2020;86(6):1165–1175. doi: 10.1111/bcp.14229

45. Papamichael K, Cheifetz AS. Therapeutic drug monitoring in patients on biologics: lessons from gastroenterology. Curr Opin Rheumatol. 2020;32(4):371–379. doi: 10.1097/BOR.0000000000000713

46. Педа Е.С., Александров Т.Л., Баранова Т.А., и соавт. Эффективность и безопасность перехода с терапии оригинальными препаратами на биосимиляры при лечении воспалительных заболеваний кишечника. Экспериментальная и клиническая гастроэнтерология. 2021;195(11):35–41. doi: 10.31146/1682-8658-ecg195-11-35-41

47. Князев О.В., Звяглова М.Ю., Каграманова А.В., и соавт. Потеря ответа и частота нежелательных явлений у пациентов с язвенным колитом и болезнью Крона при переходе с оригинального препарата инфликсимаб на его биосимиляры. Терапевтический архив. 2021;93(2):150–157. doi: 10.26442/00403660.2021.02.200624

48. Hanzel J, Jansen JM, TerSteege RWF, et al. Multiple Switches From the Originator Infliximab to Biosimilars Is Effective and Safe in Inflammatory Bowel Disease: A Prospective Multicenter Cohort Study. Inflamm Bowel Dis. 2022;28(4):495–501. doi: 10.1093/ibd/izab099

49. Cohen HP, Blauvelt A, Rifkin RM, et al. Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical

50. Outcomes. Drugs. 2018;78(4):463–478. doi: 10.1007/s40265-018-0881-y

51. Ye BD, Pesegova M, Alexeeva O, et al. Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn’s disease: an international, randomised, double-blind, phase 3 non-inferiority study. Lancet. 2019;393(10182):1699–1707. doi: 10.1016/S0140-6736(18)32196-2

52. Strik AS, van de Vrie W, Bloemsaat-Minekus JPJ, et al. Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial. Lancet Gastroenterol Hepatol. 2018;3(6):404–412. doi: 10.1016/S2468-1253(18)30082-7

53. Narula N, Marshall JK, Colombel JF, et al. Systematic Review and Meta-Analysis: Infliximab or Cyclosporine as Rescue Therapy in Patients With Severe Ulcerative Colitis Refractory to Steroids. Am J Gastroenterol. 2016;111(4):477–91. doi: 10.1038/ajg.2016.7

54. Подольская Д.В., Шапина М.В., Баранова Т.А., и соавт. Эффективность тофацитиниба в качестве «терапии спасения» у пациентов с язвенным колитом тяжелой степени. Колопроктология. 2021;20(3):43–50. doi: 10.33878/2073-7556-2021-20-3-43-50

55. Singh S, Murad MH, Fumery M, et al. Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn’s disease: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2021;6(12):1002–1014. doi: 10.1016/S2468-1253(21)00312-5

56. Singh S, Proctor D, Scott FI, et al. AGA Technical Review on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn’s Disease. Gastroenterology. 2021;160(7):2512–2556.e9. doi: 10.1053/j.gastro.2021.04.023

57. Singh S, Fumery M, Sandborn WJ, et al. Systematic review and network meta-analysis: first- and second-line biologic therapies for moderate-severe Crohn’s disease. Aliment Pharmacol Ther. 2018;48(4):394–409. doi: 10.1111/apt.14852

58. Vuyyuru SK, Kante B, Kumar P, et al. Real world analysis on the efficacy and safety of anti-tumor necrosis factor therapy in patients with stricturing Crohn’s disease. Sci Rep. 2021;11(1):11704. doi: 10.1038/s41598-021-90660-2

59. Lu C, Baraty B, Lee Robertson H, et al. Systematic review: medical therapy for fibrostenosing Crohn’s disease. Aliment Pharmacol Ther. 2020;51(12):1233–1246. doi: 10.1111/apt.15750

60. Hashash JG, Mourad FH. Positioning biologics in the management of moderate to severe Crohn’s disease. Curr Opin Gastroenterol. 2021;37(4):351–356. doi: 10.1097/MOG.0000000000000735

61. Bouguen G, Huguet A, Amiot A, et al. Efficacy and Safety of Tumor Necrosis Factor Antagonists in Treatment of Internal Fistulizing Crohn’s Disease. Clin Gastroenterol Hepatol. 2020;18(3):628–636. doi: 10.1016/j.cgh.2019.05.027

62. Lee MJ, Parker CE, Taylor SR, et al. Efficacy of Medical Therapies for Fistulizing Crohn’s Disease: Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2018;16(12):1879–1892. doi: 10.1016/j.cgh.2018.01.030

63. Strik AS, Löwenberg M, Buskens CJ, et al. Higher anti-TNF serum levels are associated with perianal fistula closure in Crohn’s disease patients. Scand J Gastroenterol. 2019;54(4):453–458. doi: 10.1080/00365521.2019.1600014

64. Tandon P, Rhee GG, Schwartz D, et al. Strategies to Optimize Anti-tumor Necrosis Factor Therapy for Perianal Fistulizing Crohn’s Disease: A Systematic Review. Dig Dis Sci. 2019;64(11):3066–3077. doi: 10.1007/s10620-019-05635-1

65. Plevris N, Jenkinson PW, Arnott ID, et al. Higher anti-tumor necrosis factor levels are associated with perianal fistula healing and fistula closure in Crohn’s disease. Eur J Gastroenterol Hepatol. 2020;32(1):32–37. doi: 10.1097/MEG.0000000000001561

66. Lewis JD, Scott FI, Brensinger CM, et al. Increased Mortality Rates With Prolonged Corticosteroid Therapy When Compared With Antitumor Necrosis Factor-α-Directed Therapy for Inflammatory Bowel Disease. Am J Gastroenterol. 2018;113(3):405–417. doi: 10.1038/ajg.2017.479

67. Nencini F, Vultaggio A, Pratesi S, et al. The Kinetics of Antidrug Antibodies, Drug Levels, and Clinical Outcomes in Infliximab-Exposed Patients with Immune-Mediated Disorders. J Allergy Clin Immunol Pract. 2018;6(6):2065–2072.e2. doi: 10.1016/j.jaip.2018.04.007

68. Fumery M, Tilmant M, Yzet C, et al. Premedication as primary prophylaxis does not influence the risk of acute infliximab infusion reactions in immune-mediated inflammatory diseases: A systematic review and meta-analysis. Dig Liver Dis. 2019;51(4):484–488. doi: 10.1016/j.dld.2018.12.002

69. Kirchgesner J, Lemaitre M, Carrat F, et al. Risk of Serious and Opportunistic Infections Associated With Treatment of Inflammatory Bowel Diseases. Gastroenterology. 2018;155(2):337–346.e10. doi: 10.1053/j.gastro.2018.04.012

70. Singh S, Facciorusso A, Dulai PS, et al. Comparative Risk of Serious Infections With Biologic and/or Immunosuppressive Therapy in Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis. Clin Gastroenterol Hepatol. 2020;18(1):69–81.e3. doi: 10.1016/j.cgh.2019.02.044

71. Khan N, Patel D, Trivedi C, et al. Overall and Comparative Risk of Herpes Zoster With Pharmacotherapy for Inflammatory Bowel Diseases: A Nationwide Cohort Study. Clin Gastroenterol Hepatol. 2018;16(12):1919–1927.e3. doi: 10.1016/j.cgh.2017.12.052

72. Holmer A, Singh S. Overall and comparative safety of biologic and immunosuppressive therapy in inflammatory bowel diseases. Expert Rev Clin Immunol. 2019;15(9):969–979. doi: 10.1080/1744666X.2019.1646127

73. Lukin D, Weiss A, Aniwan S, et al. Comparative safety profile of vedolizumab and tumour necrosis factor–antagonist therapy for inflammatory bowel disease: a multicentre consortium propensity score-matched analysis. Journal of Crohn’s and Colitis. 12(supplement_1), S036–S036. doi: 10.1093/ecco-jcc/jjx180.046

74. Bohm M, Xu R, Zhang Y, et al. Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn’s disease. Aliment Pharmacol Ther. 2020;52(4):669–681. doi: 10.1111/apt.15921

75. Kedia S, Mouli VP, Kamat N, et al. Risk of Tuberculosis in Patients With Inflammatory Bowel Disease on Infliximab or Adalimumab Is Dependent on the Local Disease Burden of Tuberculosis: A Systematic Review and Meta-Analysis. Am J Gastroenterol. 2020;115(3):340–349. doi: 10.14309/ajg.0000000000000527

76. Muller M, D’Amico F, Bonovas S, et al. TNF Inhibitors and Risk of Malignancy in Patients with Inflammatory Bowel Diseases: A Systematic Review. J Crohns Colitis. 2021;15(5):840–859. doi: 10.1093/ecco-jcc/jjaa186

77. Lichtenstein GR, Feagan BG, Cohen RD, et al. Infliximab for Crohn’s Disease: More Than 13 Years of Real-world Experience. Inflamm Bowel Dis. 2018;24(3):490–501. doi: 10.1093/ibd/izx072

78. Waljee AK, Higgins PDR, Jensen CB, et al. Anti-tumour necrosis factor-α therapy and recurrent or new primary cancers in patients with inflammatory bowel disease, rheumatoid arthritis, or psoriasis and previous cancer in Denmark: a nationwide, population-based cohort study. Lancet Gastroenterol Hepatol. 2020;5(3):276–284. doi: 10.1016/S2468-1253(19)30362-0

79. Micic D, Komaki Y, Alavanja A, et al. Risk of Cancer Recurrence Among Individuals Exposed to Antitumor Necrosis Factor Therapy: A Systematic Review and Meta-Analysis of Observational Studies. J Clin Gastroenterol. 2019;53(1):e1–e11. doi: 10.1097/MCG.0000000000000865

80. Chupin A, Perduca V, Meyer A, et al. Systematic review with meta-analysis: comparative risk of lymphoma with anti-tumour necrosis factor agents and/or thiopurines in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2020;52(8):1289–1297. doi: 10.1111/apt.16050

81. Levhar N, Ungar B, Kopylov U, et al. Propagation of EBVdriven Lymphomatous Transformation of Peripheral Blood B Cells by Immunomodulators and Biologics Used in the Treatment of Inflammatory Bowel Disease. Inflamm Bowel Dis. 2020;26(9):1330–1339. doi: 10.1093/ibd/izaa065

82. Holmer A, Singh S. Overall and comparative safety of biologic and immunosuppressive therapy in inflammatory bowel diseases. Expert Rev Clin Immunol. 2019;15(9):969–979. doi: 10.1080/1744666X.2019.1646127

83. Weizman AV, Sharma R, Afzal NM, et al. Stricturing and Fistulizing Crohn’s Disease Is Associated with Anti-tumor Necrosis FactorInduced Psoriasis in Patients with Inflammatory Bowel Disease. Dig Dis Sci. 2018;63(9):2430–2438. doi: 10.1007/s10620-018-5096-2